Ticker Details
Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
IPO Date:	December 22, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$13.47B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.89 | 1.96%
Avg Daily Range (30 D):	$1.25 | 1.54%
Avg Daily Range (90 D):	$1.10 | 1.42%

Institutional Daily Volume
Avg Daily Volume:	1.2M
Avg Daily Volume (30 D):	1.89M
Avg Daily Volume (90 D):	1.96M

Trade Size
Avg Trade Size (Sh.):	83
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	65

Institutional Trades
Total Institutional Trades:	11,849
Avg Institutional Trade:	$2.83M
Avg Institutional Trade (30 D):	$6.04M
Avg Institutional Trade (90 D):	$5.51M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$6.67M
Avg Closing Trade (30 D):	$18M
Avg Closing Trade (90 D):	$20.3M
Avg Closing Volume:	144.87K

News

Feb 19, 2026 @ 8:30 AM Global Amyotrophic Lateral Sclerosis Therapeutics ... Source: Custom Market Insights

Jan 21, 2026 @ 3:54 PM Amyloidosis Therapeutic Market to Worth Over US$ 6... Source: Astute Analytica

Jan 7, 2026 @ 4:48 PM GSK/Ionis Partnered Investigational Drug Shows Str... Source: Vandana Singh

Nov 14, 2025 @ 9:05 PM Biogen Completes Acquisition of Alcyone Therapeuti... Source: Globe Newswire

Sep 22, 2025 @ 1:06 PM Ionis Pharmaceuticals Reveals 'Unprecedented Resul... Source: Vandana Singh

Financials
	TTM	FY 2025	Q3 2025
Basic EPS	$1.58	$.63	$-.8
Diluted EPS	$1.5	$.47	$-.8
Revenue			$156.72M
Gross Profit			$154.38M
Net Income / Loss	$252.16M	$100.16M	$-128.61M
Operating Income / Loss			$-160.18M
Cost of Revenue			$2.34M
Net Cash Flow			$41.12M
PE Ratio	56.97